[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494533":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":30,"responsibleParty":48,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Jewish General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pre and post BPA","EXPERIMENTAL",null,[13],"Other: Measurement of pulmonary functional capillary surface area",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Measurement of pulmonary functional capillary surface area","Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"David Langleben, MD","CONTACT","5143407531","david.langleben@mcgill.ca",{"name":26,"role":22,"phone":27,"phoneExt":28,"email":29},"Lyda Lesenko, MD","514-340-8222","22833","llesenko@jgh.mcgill.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"David Langleben","RECRUITING","Montreal","Quebec","H3W 2C4","Canada",{"type":39,"coordinates":40},"Point",[41,42],-73.58781,45.50884,{"lat":42,"lon":41},[45,46],{"name":32,"role":22,"phone":23,"phoneExt":11,"email":24},{"name":21,"role":47,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Dr David Langleben","Professor of Medicine","100494533",false,"NCT05719415","Functional Pulmonary Capillary Surface Area in BPA for CTEPH","Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension","Inclusion Criteria:\n\n* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension\n\nExclusion Criteria:\n\n* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,\n* Presence of patent foramen ovale","ALL","18 Years","75 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"NA","Chronic thromboembolic pulmonary hypertension \\[CTEPH\\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \\[BPA\\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \\[FCSA\\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.",[68,69],"Hypertension, Pulmonary","Pulmonary Thromboembolisms","2025-09-22",{"date":72,"type":73},"2025-09-23","ACTUAL",{"date":75,"type":73},"2023-03-23",{"date":77,"type":62},"2028-01-30",{"name":5,"class":6},1]